Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical Update

Lisinopril for migraine

Benjamin H. Chen
CMAJ May 01, 2001 164 (9) 1337;
Benjamin H. Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322:19-22.

Background: Migraine, which affects an estimated 18% of women and 6% of men,1 results in significant costs to individuals and society. Current prophylactic therapies can be associated with potential side effects, but a recent observational study suggests that angiotensin-converting-enzyme (ACE) inhibitors may be effective when used prophylactically.

Question: Does lisinopril, an ACE inhibitor, prevent migraine headaches?

Design: This was a double-blind, placebo-controlled, crossover study. All patients were aged 18 to 60 years, met the diagnostic criteria for migraine established by the International Headache Society, had migraine for more than a year, had onset of migraine before the age of 50 and experienced at least 2 to 6 migraine attacks monthly. Patients who could not differentiate migraine from other forms of headache, who had used prophylactic medication recently or who had contraindications to ACE inhibitor therapy were excluded. A 4-week placebo run-in period verified the frequency of attacks. At randomization, half of the patients were assigned to receive lisinopril for 12 weeks, followed by a 2-week washout period, and then were given placebo for a final 12 weeks; the other half were given placebo first, followed by a washout period, and then lisinopril. The dosage of lisinopril was 10 mg once daily for the first week, followed by 20 mg once daily for the remaining 11 weeks.

All patients were asked to keep a daily symptom diary and were followed closely during the study period. The primary study outcomes were number of days with migraine, number of days with headache and number of hours with headache. Secondary outcomes included headache-severity index, doses of triptans and analgesics, acceptability of treatment, number of days of sick leave and quality-of-life index.

Results: Of the 60 patients eligible for randomization after the run-in period, 5 withdrew from the study and another 8 were noncompliant with the study protocol. This left 47 patients for a final evaluation of efficacy and 55 patients for an intention-to-treat analysis. The mean number of days with migraine was 6.8 during the 4-week run-in period; afterward, the mean number was 6.2 days with placebo and 4.8 with lisinopril, representing reductions of 9% (95% confidence interval [CI] –3% to 21%) with placebo and 29% (95% CI 15% to 42%) with lisinopril. The mean number of days with headache was reduced by 16% (95% CI 4% to 28%) with placebo and 30% (95% CI 19% to 42%) with lisinopril; the reductions in the mean number of hours with headache were similar. Significant differences favouring lisinopril remained when the drug was compared directly with placebo in the intention-to-treat analysis. As well, the headache-severity index and the mean doses of triptans were significantly lower with lisinopril than with placebo, and the acceptability of treatment was significantly greater with lisinopril than with placebo. There was no significant difference between the 2 drugs in the other secondary outcomes. Three patients stopped taking lisinopril because of cough.

Commentary: This crossover study, using patients both as treatment and control subjects, was able to demonstrate statistically significant differences in the primary outcomes. Potential bias due to a carry-over effect appears to have been avoided because of the washout period. The lack of difference in the number of days of sick leave, however, is disappointing. This may reflect the small size of the study, or perhaps a learned behaviour associated with a long-standing history of migraine.

Practice implications: None of the currently recommended prophylactic medications for migraine is ideal.2 The serendipitous finding that lisinopril is efficacious is therefore most welcome. ACE inhibitors are generally well tolerated in selected patients and, unlike alternative prophylactic agents such as valproic acid, are familiar to most physicians. In considering lisinopril prophylaxis, one must consider contraindications to ACE inhibitor therapy (e.g., pregnancy), as well as nonpharmacologic approaches to migraine management.3 The efficacy of lisinopril relative to other prophylactic drugs awaits future studies.

The Clinical Update section is edited by Dr. Donald Farquhar, head of the Division of Internal Medicine, Queen's University, Kingston, Ont.. The updates are written by members of the division.

References

  1. 1.↵
    Stewart WF, Lipton RB, Celetano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-62.
    OpenUrlFREE Full Text
  3. 3.↵
    Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the nonpharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 1998;159(1):47-54. Available: www.cma.ca/cmaj/vol-159/issue-1/0047.htm
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 164, Issue 9
1 May 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lisinopril for migraine
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lisinopril for migraine
Benjamin H. Chen
CMAJ May 2001, 164 (9) 1337;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Lisinopril for migraine
Benjamin H. Chen
CMAJ May 2001, 164 (9) 1337;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Early treatment of acute hepatitis C infection may lead to cure
  • Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
  • Colorectal cancer screening: you can't be positive about a negative result
Show more Clinical Update

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire